FDAsafety guidance72% confidence
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (bladder cancer) as Tyra Biosciences.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Urothelial Carcinoma
- Sub-indication
- Bladder Cancer
Related signal: Tyra Biosciences initiates Phase 2A/B trial of Dabogratinib for Low Grade Upper Tract Urothelial Carcinoma